AHA Scientific Sessions 2024
Heart-2: Early results of VERVE-102 PCSK9 gene editing
The results of seven patients entered into Heart-2, the first-in-human open label trial of a novel, investigational gene editing medicine targeting PCSK9, were presented in the AHA 2024 scientific session (Abstract 4139206)1. Patients with heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery (CAD) disease from…
read more »
LIBERATE extension: lerodalcibep maintains LDL-C reduction
Two open label extension studies of lerodalcibep, presented at the AHA 2024, showed no signs of LDL cholesterol (LDL-C) attenuation when given for more than two years. Abstract 41652211 in patients with cardiovascular disease (CVD) or at very high risk of CVD and Abstract 41701182…
read more »
YELLOW III study identifies genes to personalise evolocumab use in CAD
Coronary artery disease (CAD) patient response to evolocumab can be predicted by testing for 38 genes relating to increased fibrous cap thickness and 71 genes relating to reduced lipid core prior to starting treatment. The transcriptomic signatures identified in the latest analysis of the YELLOW…
read more »
Post hoc analysis: alirocumab benefits HeFH and T3HLP patients
Carriers of heterozygous familial hypercholesterolemia (HeFH) and type III hyperlipoproteinemia (T3HLP) benefit from alirocumab. The post hoc analysis of the ODYSSEY OUTCOMES trial, presented at the AHA 2024 meeting,1showed that major adverse cardiovascular events (MACE) and lipid reductions for patients with HeFH and T3HLP were…
read more »
